Corbus Pharmaceuticals Holdi (CRBP) Institutional Ownership & 13F Filings (Q2 2026)

CRBP ranks #4392 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

109 institutions disclose a position in CRBP, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 1.9% of its own portfolio to it.

BlackRock has added to its CRBP position for two straight quarters, increasing it by $10.3M to reach $12.5M today.

Jump Financial, LLC has trimmed its CRBP position for two straight quarters, cutting it by $248.8K while still holding $242.0K.

CRBP is up 1.8% today, and institutions have been net buyers of $31.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRBP reported a net loss of $101.9M over the trailing twelve months.

• Not yet profitable — net loss of $101.9M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$58.0M to -$101.9M
• Operating cash flow was negative, using $64.5M in cash
• Current ratio of 8.07x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range